1 recruiting, 1 withdrawn. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Withdrawn 1 |
Follow Sepsis and Coagulopathy: new trials by email Literature Review of Sepsis and Coagulopathy trials Research Report on Sepsis and Coagulopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sepsis-associated Thrombocytopenia and Platelet Transfusion (STAPT) SAT patients - Sepsis, Sepsis and Coagulopathy | Recruiting | Nanfang Hospital, Southern Medical University | 1500 | 2025-11-15 | 2026-01-30 | |
| The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy ART-123, Placebo Comparator - Placebo - Sepsis and Coagulopathy | Phase 3 | Withdrawn | Asahi Kasei Pharma America Corporation | 2019-07-01 | 2019-09-13 |
Hemostatic Disorders (2) · Sepsis (2)
Cardiovascular Diseases (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Hemorrhagic Disorders (2) · Infections (2) · Inflammation (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Systemic Inflammatory Response Syndrome (2) · Vascular Diseases (2)
ART123 (1)
Asahi Kasei Pharma America Corporation (1) · Nanfang Hospital, Southern Medical University (1)
China (1)